Headquartered in Florham Park, NJ,
Phathom Pharmaceuticals (Nasdaq: PHAT)
is a biopharmaceutical company dedicated to becoming the global leader in the management of GI-focused diseases. Founded in 2019, Phathom's lead product, vonoprazan, was in-licensed from Takeda with exclusive rights in the United States, Europe and Canada.
"We believe vonoprazan holds the potential to be a major breakthrough in the treatment of acid-related disease -- a therapeutic area that has gone largely unchanged for decades -- and where there remains significant unmet need," said Terrie Curran, President and Chief Executive Officer. "We are exploring exciting new and innovative approaches to change the treatment landscape for patients battling GI diseases such as H. pylori and erosive esophagitis."
Vonoprazan is a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. Vonoprazan has the potential to be the first gastric, anti-secretory agent from a new class approved in the United States, Europe or Canada in over 30 years. In April 2021, Phathom
successfully completed a pivotal PHALCON-HP Phase 3 trial in H. pylori infection and just recently submitted New Drug Applications (NDAs) with the U.S. FDA. The company is now preparing for a commercial launch anticipated in the second half of 2022.
"These data will be followed closely by the disclosure of Phathom's pivotal PHALCON-EE Phase 3 clinical trial in erosive esophagitis expected in October of this year," said Azmi Nabulsi, M.D., Chief Operating Officer. "We are also running a Phase 2 trial in nonerosive reflux disease (NERD) with plans for a Phase 3 trial in 2022, in addition to continuing to evaluate the development of vonoprazan for other acid-related disorders."
Phathom's development programs for vonoprazan build upon a solid foundation of studies of over 8,000 patients around the world. Vonoprazan is currently approved in Japan and numerous other countries in Asia and Latin America. More than 25MM patients globally have received treatment with vonoprazan which has shown to have rapid, potent and durable anti-secretory effects with an attractive safety profile.
Phathom established its headquarters in New Jersey due to the strategic benefits the area provides life sciences companies. "We were initially founded with a small, strong team of experienced individuals leading our clinical trials in Buffalo Grove, Illinois. Recognizing our potential for rapid growth and evolution to a commercial-stage organization, we made the decision to establish our corporate headquarters in Florham Park, NJ, where we had access to a wealth of industry talent across all aspects of the pharmaceutical business," said Curran. "In addition, Phathom chose to locate its headquarters in New Jersey because of the existing and scalable office space as well as proximity to New York City and numerous international airports. "Our New Jersey headquarters are strategically located near numerous transportation hubs where we can easily travel to meet partners, attend medical congresses and connect with our employees in our other U.S. locations," added Curran.
"We are thrilled to have Phathom as part of New Jersey's vibrant life sciences ecosystem," said BioNJ President and CEO, Debbie Hart. "The work being done by Phathon offers patients around the globe suffering with GI-focused diseases hope for a better life. We wish Ms. Curran, Dr. Nabulsi and the full Phathon Team continued success."
While Phathom plans to build a fully-fledged pharmaceutical company, they may seek a partner in Europe. Phathom is growing exponentially and expanding the organization across virtually all functions and disciplines.
